Blog
Unleashing Women’s Potential in Advanced Therapies
π’ Women in advanced therapies: 'Get comfortable being uncomfortable' and drive change. πͺ Seek out challenging opportunities, take risks, and make a difference! ππππββοΈ
Alvotech’s Biosimilar Plant Receives Second FDA Violation
π¬π¨ Alvotech, a biopharmaceutical company, receives another FDA observation at its biosimilar plant, potentially delaying product approval.
Exciting Collaboration Boosts Excellos’ Cell Therapy!
π£ CDMO Excellos teams up with Vitalant for cell therapy advancements! ππ§ͺ Excellos' programs will benefit from Vitalant's services, boosting their biotech offerings. π
Oligo Factory MA Plant Gets GMP Greenlight!
π± Exciting news! The Oligo Factory MA plant π has received the GMP greenlight π for biotech industry. Get ready for innovation! π
Game-Changing RNA Vaccine Success: How One Company Perfected Manufacturing
π° Arcturus Therapeutics, the pioneer in self-amplifying mRNA (saRNA) vaccines, credits perfecting manufacturing techniques for success. πππ¬
Major Leadership Changes in Oncology Biotechs: What’s Next?
π° Ins & Outs: C-suite changes across oncology biotechs explores recent leadership transitions in cancer-focused biotech companies. π₯ππ₯π§ͺπ¬
Breaking: CGTs Accessibility Challenges Uncovered in 2023
π°CGTs in 2023: Floodgates open but patient access still sticky highlights challenges in patient access to CGTs. π₯π‘π°βοΈπ€π
Lonza shuts down Swiss manufacturing site cutting 190 jobs
π’ Lonza is decommissioning its mammalian manufacturing site in Visp, Switzerland, after 30 years of operation. πβ This decision is driven by market dynamics and the need for flexibility. β However, Lonza will focus on other sites and genecell therapies. π Around 190 jobs will be lost.
Revolutionary Cancer Treatment Process: Cost-Effective and Scalable!
π’ Researchers at the University of Ottawa have developed an innovative production process for cancer treatments using NK cells and EVs. π©Ί This cost-effective and scalable breakthrough could revolutionize immunotherapies. ππ
Revolutionary Partnership Boosts Spider Silk Production
π AMSilk GmbH and 21st.BIO AS are partnering to accelerate the production of spider silk-based proteins. π¬π‘π
